GOVX GeoVax Labs, Inc.

NASDAQ
$2.01

GeoVax Labs, Inc. (GOVX) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $24.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.3% since its last earnings release on November 12, 2026.

GeoVax Labs Beat Consensus Estimates
Thursday, November 12, 2026 · 12:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · After Close
Earnings Whisper
-
vs ($24.10)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.02

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About GeoVax Labs, Inc.

GeoVax Labs, Inc., is a development stage biotechnology company. It is engaged in developing human vaccines for diseases caused by Human Immunodeficiency Virus (HIV).

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.